Supplemental Figure 2 from Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma

Authors :: Emanual Maverakis
Brian Jonas
Aaron Rosenberg
Ann Brunson
Alina Marusina
Alexander Merleev
Guilluame Luxardi
Paul Kaesberg
Christina Poh
Joseph M. Tuscano
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Gating strategy for analysis of live lymphocytes.

Full Text Access

Tools